JanOne Inc. (JAN)
| Market Cap | 24.59M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -20.04M |
| Shares Out | 12.17M |
| EPS (ttm) | -5.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 66,445 |
| Open | 2.110 |
| Previous Close | 2.140 |
| Day's Range | 1.970 - 2.190 |
| 52-Week Range | 0.220 - 5.260 |
| Beta | 2.10 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 27, 2024 |
About JAN
JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. Its lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. The company was formerly known as Applianc... [Read more]
Financial Performance
Financial StatementsNews
JanOne Appoints Vay Tham as its Chief Revenue Officer and President of its Fintech Subsidiary, ALT5 Sigma
LAS VEGAS , June 26, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, is pleased to announce that it has appointed Mr. Vay Tham ...
ALT5 SIGMA, A JANONE COMPANY, ADDS PREPAID VISA®️ CARD INTEGRATION TO ALT5 SETTLEMENT PLATFORM
LAS VEGAS, June 25, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, announced today that its wholly-owned subsidiary, ALT5 Sigm...
JanOne's Subsidiary, Alt5, Reports 91% year over year increase in Transaction Volume to US $289 million for April and May 2024
LAS VEGAS , June 13, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, released today its wholly-owned subsidiary, ALT5 Sigma, tr...
ALT5 Sigma, a wholly-owned subsidiary of JanOne, Launches ALT5 Settlement Platform aimed at the untapped $27.3 Billion Global Digital Content Creation Market
LAS VEGAS , June 11, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, announced today that its wholly-owned subsidiary, ALT5 Sig...
JanOne Inc. added to the Russell Microcap® Index
LAS VEGAS , June 3, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, announced today that it has been added to the Russell Micro...
ALT 5 Sigma, a wholly-owned subsidiary of JanOne to Present at the iFX Expo, the World's largest online trading conference and tradeshow
LAS VEGAS, May 28, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN) a multidisciplinary organization with a focus on healthcare and fintech, announced today that its Fintech subsidiary, ALT 5 Sigma, wil...
JanOne Closes Acquisition of ALT 5 Sigma Inc., a Leading Next Generation Blockchain Fintech
LAS VEGAS , May 16, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN) announced today it has closed its previously announced acquisition of blockchain financial technology provider, ALT 5 Sigma Inc., and...
JanOne Regains Compliance with Nasdaq's Listing Requirements
LAS VEGAS, March 15, 2024 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, today announc...
JanOne to Present at the Dawson James 8th Annual Investment Conference
Chief Medical Officer Dr. Amol Soin will explain innovative approaches to pain management and JanOne's development of non-addicting treatments for pain LAS VEGAS , Sept. 21, 2023 /PRNewswire/ -- JanOn...
JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment Conference
Chief Medical Officer Dr. Amol Soin will discuss innovative approaches to pain management and JanOne's development of non-addicting treatments for pain LAS VEGAS , Aug. 31, 2023 /PRNewswire/ -- JanOne...
JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain
The Broad Patent Coverage is a Major Milestone for the Commercial Success of Jan123 LAS VEGAS , Aug. 29, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the visionary biotech company dedicated to discoveri...
JanOne Wins "Best Abstract" Award at the Ohio Society of Interventional Pain Physicians Annual Meeting
Abstract explained Jan101's statistically significant reduction in pain and improvement in nerve conduction velocity in prior Phase II study. LAS VEGAS , Aug. 25, 2023 /PRNewswire/ -- JanOne (Nasdaq: ...
JanOne Technologies Announces Closing of Registered Direct Offering Priced At-The-Market under Nasdaq Rules
LAS VEGAS, Aug. 22, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN) (the "Company"), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of...
JanOne Technologies Announces Registered Direct Offering Priced At-The-Market under Nasdaq Rules
LAS VEGAS , Aug. 18, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN) (the "Company"), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes o...
JanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual Meeting
JAN101 Showed Statistically Significant Reduction in Pain and Improvement in Nerve Conduction Velocity in Prior Phase II study. LAS VEGAS , Aug. 18, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopha...
JanOne files international patent application for methods of using low dose naltrexone to treat chronic pain
Patent filing marks another milestone in becoming a world leader in pain management LAS VEGAS , June 28, 2023 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a biopharmaceutical company that is developing ...
JanOne Completes Pre-IND Meeting with FDA on Jan123
JanOne (Nasdaq: JAN), the biopharmaceutical innovator specializing in non-addicting painkillers and new treatments for the causes of pain, has completed a successful pre-IND meeting with the FDA regar...
JanOne to Present Data On Its Two Non-Opioid Drug Candidates at The Appalachian Region Spine and Pain Meeting on Drug Development Programs to Treat Pain on April 15, 2023
LAS VEGAS , April 13, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), Dr. Amol Soin, Chief Medical Officer of JanOne, will be presenting at the Appalachian Region Spine and Pain Meeting in Sulfur Springs, ...
JanOne Technologies Announces Closing of Registered Direct Offering of Common Stock Priced At-The-Market
LAS VEGAS , March 24, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today a...
JanOne Welcomes John Bonfiglio -- Veteran Biotech Executive, Deal Maker and Strategist -- to Top Management Team
Bonfiglio is known for raising capital, building start-ups, and leading successful biotech companies as CEO and COO. LAS VEGAS , March 23, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmace...
JanOne Technologies Announces Registered Direct Offering of Common Stock Priced At-The-Market
LAS VEGAS , March 23, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today a...
JanOne Sells Legacy Business ARCA Recycling to Concentrate on Growing BioPharm Businesses
Sale reduces liabilities by $17.6 million and entails at least $24 Million in future payments LAS VEGAS , March 22, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing...
JanOne to Present Important Trial Results at Annual Meeting of American Society of Interventional Pain Physicians
JAN 123's in vitro study on low dose naltrexone vies for the Society's "Best Research Abstract of the Year" LAS VEGAS , Feb. 22, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical compan...
JanOne Charts Ambitious Strategic Course for Non-Addictive Pain Management
In meetings hosted by Nasdaq MarketSite , the company reviewed its drug development programs that fight the opioid crisis through pharmaceuticals that reduce pain without causing addiction. LAS VEGAS ...
JanOne Inc. Completes Acquisition of Soin Therapeutics, LLC
The acquisition of Soin provides JanOne with its second, late stage clinical stage asset LAS VEGAS , Jan. 10, 2023 /PRNewswire/ -- JanOne Inc. ("JanOne") (Nasdaq: JAN), a company that focuses on the d...